Evidence map›Paper›PMID 33924486›Full record

ArticleCancers2021

Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition.

Antonella Catalano, Mojca Adlesic, Thorsten Kaltenbacher, Rhena F U Klar, Joachim Albers, Philipp Seidel, Laura P Brandt, Tomas Hejhal, Philipp Busenhart, Niklas Röhner and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 2 countries.

Antonella CatalanoDepartment of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
Mojca AdlesicDepartment of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
Thorsten KaltenbacherInstitute of Molecular Medicine and Cell Research (IMMZ), Faculty of Medicine, University of Freiburg, 79104 Freiburg, Germany.ORCID 0000-0001-8233-4749
Rhena F U KlarDepartment of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
Joachim AlbersInstitute of Physiology, University of Zurich, 8057 Zurich, Switzerland.
Philipp SeidelDepartment of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.ORCID 0000-0003-0097-9768
Laura P BrandtInstitute of Physiology, University of Zurich, 8057 Zurich, Switzerland.
Tomas HejhalInstitute of Physiology, University of Zurich, 8057 Zurich, Switzerland.
Philipp BusenhartInstitute of Physiology, University of Zurich, 8057 Zurich, Switzerland.
Niklas RöhnerDepartment of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
Kyra ZodelDepartment of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
Kornelia FritschDepartment of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
Peter J WildDepartment of Pathology and Molecular Pathology, University Hospital Zurich, 8006 Zurich, Switzerland.
Justus DuysterDepartment of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
Ralph FritschDepartment of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
Tilman BrummerSignaling Research Centre BIOSS, University of Freiburg, 79104 Freiburg, Germany.ORCID 0000-0003-4387-7905
Ian J FrewDepartment of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.ORCID 0000-0003-2735-5509
University of Freiburg · DEUniversity of Zurich · CHUniversity Hospital of Zurich · CH

Funding

Deutsche Forschungsgemeinschaft BIOSS Excellence ClusterDeutsche Forschungsgemeinschaft BR 3662/5-1Deutsche Forschungsgemeinschaft CRC850
6 · The paper itself

Abstract

Oncogenic mutations in

Indexed as

drug resistanceERK inhibitorMEK inhibitormetastasismouse tumor modeloncogenic RASpancreatic ductal adenocarcinomaundifferentiated pleomorphic sarcoma

Identifiers

PMID33924486
PMCPMC8069437
OpenAlexW3156889424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.